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Background: In advanced metastatic colorectal adenocarcinoma, the addition of a neo-adjuvant systemic
treatment to surgery might translate into a survival advantage, although this is yet to be confirmed by ongoing
randomized trials. The objective of this study was to assess the effects of preoperative systemic chemotherapy
on the morphology of non-tumoral liver.
Patients and methods: A large series of surgically resected liver metastases (n = 153) was selected. Light
microscopy, electron microscopy, and immunohistochemistry using antibodies against endothelial cells
(CD31) and hepatic stellate cells (α-SM actin, CRBP-1) were performed to identify sinusoidal wall integrity.
Results: We found that 44 (51%) of the 87 post-chemotherapic liver resection specimens had sinusoidal
dilatation and hemorrhage, related to rupture of the sinusoidal barrier. In contrast, the 66 livers treated by
surgery alone remained normal. In 21 out of the 44 post-chemotherapy patients (48%), perisinusoidal and veno-
occlusive fibrosis also developed. Sinusoidal injury persisted several months after end of chemotherapy, and
fibrosis may progress. Development of lesions was strongly correlated to the use of oxaliplatin; 34 out of
43 patients (78%) treated with this drug showed striking sinusoidal alterations.
Conclusions: Systemic neo-adjuvant chemotherapy in metastatic colorectal cancer frequently causes morpho-
logical lesions involving hepatic microvasculature. Sinusoidal obstruction, complicated by perisinusoidal fibrosis
and veno-occlusive lesion of the non-tumoral liver revealed by this study, should be included in the list of the
adverse side-effects of colorectal systemic chemotherapy, in particular related to the use of oxaliplatin.
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Introduction
Liver metastasis is the most common complication from colorectal
cancer and a major contribution to mortality due to this disease.
Approximately 60% of patients with colorectal cancer develop
metastases, and in ∼30% the liver is the only site of metastatic
involvement [1]. Hepatic resection currently remains the treatment
that offers the best chance of long-term survival to such patients
[2, 3].
Increasing numbers of liver metastases are now considered
surgically resectable. Various factors explain this trend: progress
of surgical techniques, better knowledge of the functional anatomy
of the liver, detection of metastases at an earlier stage, intro-
duction of new therapeutic approaches (e.g. cryosurgery, radio-
frequency) and use of chemotherapy before resection. This latter
approach, aimed at the reduction of the size of metastases, allows
the resection of an additional 16% of metastases previously
deemed unresectable [4].
Despite the large number of drugs available, only a few agents
have been found to be active in advanced colorectal cancer. The
standard treatment for advanced colorectal cancer has been
5-fluorouracil (5-FU)-based chemotherapy combined or not with
leucovorin. Recently, new therapeutic approaches have been
introduced. These include agents with mechanisms of action
unrelated to thymidylate synthetase, such as irinotecan, a topoiso-
merase I inhibitor [5], and oxaliplatin, the only platinum derivative
with significant activity in colorectal cancer [6]. Combined with
5-FU and leucovorin, both irinotecan and oxaliplatin have led to a
significant improvement in terms of response rate, disease-free
and even overall survival in metastatic disease, and have become
standard of care in this setting. Considerable enthusiasm for the
use of these new systemic combinations in a neo-adjuvant setting
before curative surgical removal of liver metastases has also
generated a large set of very encouraging data, but only in the
context of non-controlled trials, and confirmation in proper ran-
domized trials is still awaited [7–11].
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Despite the increasingly extensive use of neo-adjuvant chemo-
therapy in advanced colorectal cancer, its functional and
histopathological effects on the liver remain inadequately
described. The aim of this study was to attempt to fill this gap by
analyzing the morphological effects of preoperative systemic
chemotherapy on the non-tumoral hepatic parenchyma, in a large
series of livers resected for metastatic involvement by colon
carcinoma. The study was conducted in two centers that have used
preoperative chemotherapy since 1995.
Materials and methods
Patients
We reviewed the clinical data for all patients who had undergone surgical liver
resection for hepatic metastases from colorectal carcinoma between 1994 and
2002 at the University Hospital, Geneva, Switzerland (n = 82) and at the
Hôpital Cochin, Paris, France (n = 92). Our study was performed in accord-
ance with the ethical standards of the Declaration of Helsinki of the World
Medical Association. After evaluating clinical data, we examined the patho-
logical material available for each case, and determined that of the 174 resections,
153 had adequate clinical information and sufficient material for pathological
studies. The 21 excluded cases had incomplete clinical data and/or <2 cm2 of
non-tumoral liver tissue on the slide analyzable for morphological evaluation.
The group included 93 men and 60 women. The mean age was 62 years
(range 36–80). The liver resections consisted of 80 right and 31 left hepa-
tectomies, and 42 segment-oriented resections. Vascular exclusion (Pringles’
maneuver or vascular efferent exclusion) was performed during surgery in
55 cases. Preoperative portal embolization was performed in six cases. Eighteen
patients underwent two or more liver resections, because of recurrence of
hepatic metastases in 16 cases, and two time resections in two cases.
Surgical resection was the only treatment undergone for the metastases in
66 cases. Systemic chemotherapy was undergone before hepatic surgery in
87 cases. Several different protocols were used: 16 patients received oxaliplatin
in combination with irinotecan and 5-FU; 27 received oxaliplatin in combin-
ation with 5-FU; 17 received irinotecan in combination with 5-FU; and
27 received 5-FU alone (Table 1). The administration was exclusively intra-
venous.
Tissues
All archival slides (originally prepared from formalin-fixed, paraffin-embedded
tissue) were reviewed, and representative slides of non-tumoral tissue located
at distance of the tumor were selected for quantitation of the lesions and immuno-
histochemical studies. The morphological analyses were based on hematoxylin
and eosin, Masson trichrome and reticulin stainings. Slides were examined
blindly by pathologists working on the study (L.Rubbia-Brandt, B.Terris,
V.Audard and P.Sartoretti), who were unaware of the subject’s clinical data;
specifically, no information was available on the administration of preoperative
chemotherapy.
The following histological features were evaluated: sinusoidal dilatation,
centrilobular vein fibrosis, perisinusoidal fibrosis, nodular hepatic regeneration,
hepatocellular necrosis and steatosis. Sinusoidal dilatation was graded semi-
quantitatively as follows: 0, absent; 1, mild (centrilobular involvement limited
to one-third of the lobular surface); 2, moderate (centrilobular involvement
extending in two-thirds of the lobular surface); 3, severe (complete lobular
involvement). Steatosis was estimated as the percentage of involved hepato-
cytes, and was categorized as follows: 0, absent; 1, mild (steatosis in <30% of
the hepatocytes); 2, moderate (steatosis in 30–60% of the hepatocytes);
3, severe (steatosis in >60% of the hepatocytes).
The χ2-test was used to correlate the different groups of patients according
to the presence or not of preoperative treatment, and the type of chemotherapy
versus the presence of sinusoidal dilatation. A result was considered statis-
tically significant if P <0.05.
Immunostaining
Five cases of hepatectomies showing representative sinusoidal lesions and five
control cases of hepatectomies for colorectal metastasis without lesions were
selected for immunohistochemical studies, in order to better characterize the
morphology of the sinusoidal lesions.
For immunostaining, additional serial 3–5 µm sections were prepared.
Sections were mounted on silane-coated glass slides, air-dried overnight,
deparaffinized, rehydrated and pretreated with H2O2/methanol to block endo-
genous peroxidase activity. The following primary antibodies were used:
mouse monoclonal α-smooth muscle (α-SM) actin (DakoCytomation, Zug,
Switzerland; 1:400 dilution); rabbit polyclonal cellular retinol binding protein-
1 (CRBP-1) (gift from Professor G. Gabbiani; 1:200 dilution); and mouse
monoclonal anti-human CD31 (DakoCytomation; 1:50 dilution). For α-SM
actin and CD31 antibodies, microwave pretreatment was used. For CRBP-1,
pretreatment with a pressure cooker was performed. Sections were incubated
for 1 h at room temperature with the diluted primary antibodies, which were
then revealed by ENVISION (DakoCytomation). Peroxidase activity was
revealed with 30% 3,3′-diaminobenzidine as chromogen in phosphate-
buffered saline containing 0.015% H2O2. Sections were weakly counter-
stained with Mayer’s hematoxylin and mounted in Eukitt (Kindler GmbH,
Freiburg, Germany). Negative controls were prepared by omitting the first
antibodies.
Electron microscopy
During the study period, new available liver specimens with macroscopic
lesions were fixed in glutaraldehyde and embedded in Epon. Semi-thin
sections were stained with Toluidine Blue. Regions of the liver with represent-
ative sinusoidal lesion were selected for thin sections. Thin sections were
treated with uranyl acetate and lead citrate and examined using a Zeiss electron
microscope (EM CR 10; Zeiss).
Results
Histopathological aspects
Among the 153 hepatic resections analyzed, 44 (29%) exhibited
histological lesions in the non-tumoral liver. They consisted
mainly of injury in centrilobular zones characterized by severe
sinusoidal dilatation with erythrocytes congestion, occasionally
Table 1. Types of intravenous chemotherapy undergone before surgical 
resection
5-FU, 5-fluorouracil.
Type of chemotherapy Number of 
cases
No hepatic 
lesion (%)
Hepatic 
lesions (%)
Total without chemotherapy 66 66 (100) 0 (0)
Total with chemotherapy 87 43 (49) 44 (51)
5-FU alone 27 21 (78) 6 (22)
5-FU and irinotecan 17 13 (77) 4 (23)
5-FU and oxaliplatin 27 7 (26) 20 (74)
5-FU, oxaliplatin and 
irinotecan
16 2 (12) 14 (88)
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accompanied by perisinusoidal fibrosis and fibrotic venular
occlusion (Figure 1A and B). In most cases, there was an irregular
distribution of the lesions, with presence of abnormal lobules
intermingled with intact lobules. Sinusoidal congestion was grade 1
in 16 patients, grade 2 in 16 cases and grade 3 in 12 patients. In
some centrilobular areas of cases with grade 2 or 3, the severity of
sinusoidal distension was accompanied by extravasation of eryth-
rocytes, characterized by erythrocytes lining down directly along
hepatocellular plates (Figure 2A). Atrophic hepatocellular plates
or few necrotic cells bordered dilated areas. In atrophic zones, the
reticulin staining was focally increased, corresponding to peri-
sinusoidal fibrosis (data not shown). However, a component of
parenchymal collapse with consequent visualization of the reticulin
cannot be completely ruled out. Several centrilobular veins were
also clearly affected by fibrosis, resulting in variable degrees of
luminal occlusion (Figure 1B). These patterns were observed in
21 out of 44 patients (48%). The periportal lobular zones appeared
with widened hepatocellular plates; these regenerative foci
involved the affected lobules in most of the cases, but reached an
aspect of diffuse nodular regenerative hyperplasia (NRH) in seven
cases (data not shown). In the most florid cases, diffuse heterogenous
hemorrhagic foci and parenchymal nodularity were evident even
macroscopically (Figure 1C). Steatosis was present in 75 of the
153 patients (49%). It was grade 1 in 44 of 75 (59%) cases, grade
2 in 22 of 75 (29%) cases and grade 3 in nine of 75 (12%) cases.
Immunohistochemical studies
In control liver without sinusoidal lesions, CD31+ endothelial
cells were present in portal tract and vessel walls (hepatic artery,
portal vein and centro-lobular vein), and diffuse along lobular
sinusoid. α-SM actin-positive cells were observed in vessel walls
(data not shown). Sparse hepatic stellate cells (HSC) positive for
α-SM actin were focally observed in a small proportion of the
lobules. In the lobule, CRBP-1 was expressed at a high level in
HSC (data not shown).
In livers with sinusoidal lesions, CD31 positivity was absent
from areas of severe sinusoidal dilatation. In contrast, CRBP-1
showed the same distribution as observed in normal liver (data not
shown). These results suggest loss of sinusoidal endothelial cells
but a persistence of perisinusoidal HSC along dilated sinusoid.
However, the expression of α-SM actin in HSC was drastically
modified compared with normal liver. A strong reactivity was
Figure 1. (A) Low-power examination on trichrome Masson stain of the liver revealed areas of sinusoidal congestion involving centrilobular and 
mediolobular lobular surface. At high-power examination, sinusoidal congestion is severe, outlined by atrophic hepatocyte trabeculae. (B) The small hepatic 
vein is partially occluded by fibrous tissue; on the cut surface, the liver around and at the distance of the metastasis is diffusely nodular. (C) Nodules are 
outlined by congested areas. (D) In a third hepatectomy, performed in one patient 49 months after chemotherapy, extensive fibrous septa delimit parenchymal 
nodules on trichrome Masson.
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present in almost all HSC within the lobules, and was present both
along dilated sinusoids and intact sinusoids (data not shown). This
indicates an activated state of HSC.
Electron microscopy
Extensive ultrastructural abnormalities of sinusoidal endothelial
cells were observed. Endothelial cells were rounded up and
swollen; their nuclei showed peripheral chromatin condensation,
suggesting the apoptotic process (Figure 2A). Areas of sinusoidal
dilatation showed diffuse discontinuities along the endothelial
sinusoidal lining, allowing red blood cell extravasation in the
widened Disse’s spaces (Figure 2A and B). A neodeposition of
extracellular matrix components in Disse’s spaces was evident,
mainly by fine collagen bundles (Figure 2A). A striking feature
was the presence of numerous cytoplasmic blebs obstructing the
sinusoidal lumen, several of them containing organelles (Figure 2B).
In contrast, hepatocytes were better preserved, showing mainly a
loss of hepatocyte microvilli.
Correlation of histological findings with type of 
chemotherapy and clinical data
Centrilobular lesions were observed in 44 of the 87 (51%) patients
who received chemotherapy. No centrilobular lesions were
observed in any of the 66 patients treated by surgery alone, including
those in whom preoperative portal embolization or preoperative
vascular exclusion had been performed (Table 1). Among the
different protocols of chemotherapy, a significant correlation was
detected between the presence of liver lesions and the use of
oxaliplatin: 34 of the 43 (79%) patients treated with oxaliplatin
developed lesions, as opposed to 10 of the 44 (23%) who did not
(P <0.001) (Table 1). The amount of oxaliplatin received by our
population was quantified as cumulative dose expressed in mg/m2;
the range was 280–1600 mg/m2. No correlation was found
between the cumulative dose of oxaliplatin and the development
of sinusoidal lesions (P >0.05).
The mean interval between last administration of chemotherapy
and surgical resection was 35 days (range 16–110). Hepatic
sinusoidal lesions persisted up to 4 months after last chemo-
therapy. Steatosis was observed in 42 of the cases 87 (48%) with
chemotherapy and in 33 of the 66 cases (50%) without chemo-
therapy (P >0.01).
Evolution of the liver lesions
To appreciate the evolution of the liver lesions at a time distant
from the initial chemotherapy, we analyzed the 18 cases who
underwent iterative hepatic surgery. In three patients treated by
surgery alone, no centrilobular lesions were observed in the subse-
quent hepatectomies. Among the 15 remaining patients, nine had
initial lesions on the first hepatectomy. Six of them received new
cycles of preoperative chemotherapy, which did not allow the
evaluation of the natural evolution of the lesions at a time distant
from the end of chemotherapy. The three remaining patients
showing lesions on the first liver resection had iterative hepatic
resections for recurrence of liver metastasis with surgery as the
only treatment. The second hepatectomies were performed 5, 11
and 17 months after the first resection, respectively. A third hepa-
tectomy was performed in one patient 32 months after the second
one. There was a persistence of sinusoidal dilatation in one case
and fibrosis in two cases. In one of these patients, the fibrosis pro-
gressed; it no longer remained confined to the centrilobular zones,
but it also extended to the rest of the lobule with centro-centro and
porto-centro bridging fibrosis, reaching a cirrhotic configuration
in the third hepatectomy (Figure 1D). In this patient, α-SM actin-
positive HSC were diffusely present along the lobules, while the
pattern of CRBP-1 and CD31 expression was similar to that found
in normal liver (data not shown). Moreover, this patient was hepa-
titis B and C virus negative, and had no history of alcohol abuse.
Discussion
At present, surgery is the only curative option for the treatment of
liver metastases from primary colorectal carcinoma. Preoperative
Figure 2. (A) A sinusoid containing four red blood cells. The perisinusoidal space of Disse (star) is extensively dilated and contains several erythrocytes in 
close contact with hepatocytes (arrow). Endothelial cells are rounded up and protrude into the lumen of the sinusoid (arrow head). Magnification, ×7200.     
(B) A sinusoid containing two red blood cells. The rest of the sinusoid lumen is filled with cytoplasmic blebs, two of which contain organelles (arrow heads). 
The perisinusoidal space is enlarged and contains collagen fibers. Magnification, ×7200.
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chemotherapy is used to achieve conversion from unresectability
to resectability of hepatic metastases, thus increasing the number
of patients who can benefit from surgical intervention [4, 12].
Expanding the body of data gathered indicates that in metastatic
disease, this combined strategy might be beneficial on the overall
rate of recurrence [7, 8, 10, 11]. Approximately 40% of patients
who undergo this treatment can be expected to survive 5 years or
longer [12]; this advantage could have an effect on the outcome of
resected patients, and randomized trials testing this hypothesis are
currently ongoing. In addition, surgery is also applied in liver
metastasis recurrence, and the number of cases of iterative resec-
tions, often preceded by new cycles of chemotherapy, is increasing.
Therefore, it is important to be aware of, and to prevent, the possible
harmful side-effects of the chemotherapeutic regimens adminis-
tered to these patients.
The results of this study show that neo-adjuvant chemotherapy
in patients with metastatic colon cancer may induce important
sinusoidal obstruction associated with sinusoidal fibrosis and
veno-occlusive lesions, occasionally with nodular regenerative
hyperplasia. In our population, this effect was particularly marked
in the livers of patients treated with protocols that included oxali-
platin. No such lesions were present in the resected livers from
patients who had been treated by surgery alone.
Whereas hepatocellular carcinomas usually arise from a back-
ground of fibrosis or cirrhosis, colon cancer metastases often
affect normal livers. Frequently in our experience, however,
surgeons report gross abnormalities, such as soft, congestive or
even pseudocirrhotic livers, which compel them to limit the exten-
sion of the resection. Not uncommonly, frozen-section examin-
ations requested to evaluate the non-tumoral liver prior to the
performance of the resection indicate sinusoidal lesions.
To our knowledge, these abnormalities have not been system-
atically investigated. Only the hepatotoxic effects of 5-FU have
received much attention: Washington et al. [13] reported in 1993
the development of NRH in five patients treated with 5-FU; bile
duct fibrosis and stenosis secondary to hepatic intra-arterial 5-FU
treatment have also been reported [14]. Furthermore, experimental
studies with the use of intra-arterial 5-FU perfusion in rabbits [15]
have shown endothelial toxicity resulting in disruption of the
endothelium of small arteries, patchy exposure of the subendo-
thelium and foci of thrombus formation.
The sinusoidal lesions we observed here were morphologically
similar to those seen in veno-occlusive disease, a condition that
occurs mainly as a complication of high-dose chemotherapy in the
setting of stem-cell transplantation, and recently renamed by
DeLeve et al. [16–18] as sinusoidal obstruction syndrome (SOS).
In our series, the prevalence of SOS in patients who received pre-
operative chemotherapy was 51%. This figure is substantially
higher than the 10–20% reported in patients who underwent bone
marrow transplantation for lympho-hematological malignancies
[17].
The intensity of the sinusoidal dilatation and congestion was
occasionally severe, and included the disruption of the sinusoidal
wall integrity. This latter finding was well illustrated by the
extravasation of erythrocytes in Disse’s space and by immuno-
histochemical and ultrastructural studies, which showed the com-
plete absence of endothelial lining in the dilated areas. HSC,
however, remain present in the perisinusoidal space, as demon-
strated by the preserved expression of CRBP-1, a new marker of
HSC [19]. Extensive collagenization of perisinusoidal space and
centrilobular vein was occasionally identified. This fibrogenesis
was highlighted by the presence of α-SM actin-positive HSC, an
activation marker of fibrogenic cells, both around sinusoidal
dilated areas and in other areas of the lobule. This observation is in
agreement with a previous description of veno-occlusive diseases
in humans [20].
Based our observations, we propose the hypothesis that an
initial toxic injury to the sinusoidal endothelial cells results in
sinusoidal wall disruption; this may be followed by an activation
of HSC and the deposition of matrix in the sinusoids. Obstruction
was caused by erythrocytes sloughing, but also by blebs, charac-
terized by free fragments of cytoplasmic processes, occasionally
containing cellular organelles. Ultrastructural bleb formation has
been described in an experimental rat model of hepatic sinusoidal
drug toxicity [21].
In addition to sinusoidal lesions, we also observed areas of
hepatic regeneration, which reached a pattern of NRH in seven
cases. NRH has been reported in one published series of patients
who received preoperative 5-FU chemotherapy for metastatic
carcinoma of the colon, with a frequency equivalent to that of our
study [13]. The pathogenesis of NRH is believed to be related to
modifications of intrahepatic blood flow [22, 23]. When
symptomatic, patients develop signs of portal hypertension and
cholestasis with elevated alkaline phosphatase. Despite the fact
that NRH could become clinically evident a long time after
chemotherapy, the latter is under investigation in our study
population, as well as possible delayed hepatic regeneration after
surgical resection.
Different chemotherapy protocols for advanced colorectal
carcinoma have been developed over the last decade. To date,
oxaliplatin, a novel platinum complex, has proven to be a safe and
effective therapy for colorectal cancer in combination with 5-FU
[24], and its side-effects have been easy to manage with appropriate
awareness from patients and care providers. During clinical trials,
the adverse events most often reported were hematological toxicity,
gastrointestinal tract toxicity and a neuropathy, none of which has
been observed with other therapeutic platinum derivatives [25]. In
our series, we found a significant correlation between the use of
oxaliplatin and the development of severe sinusoidal injury.
Carboplatin, another alkylating agent of the cisplatin family, has
been rarely associated with the development of veno-occlusive
disease in patients who have undergone stem-cell transplantation
[26]. However, to our knowledge this is the first report of a series
of patients with significant hepatic adverse effects from oxaliplatin.
Several interpretations of these data are possible. First, no targeted
liver biopsy studies have been performed in patients with colon
cancer who have received chemotherapy that included oxaliplatin.
Such studies would be difficult to justify from an ethical view-
point, and may never be performed. For our study we had access to
extensive sampling from the resected livers, which allowed accurate
histopathological examination and therefore increased the likeli-
hood of detecting even subtle abnormalities. A second possibility
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is that oxaliplatin alone may in fact have little or no liver toxicity,
but in combination with other chemotherapeutic agents (e.g. 5-FU)
a synergic effect may occur. This is unlikely, because most
chemotherapy protocols for colon cancer include a combination
of different drugs, and serious liver toxicity has not been reported.
Another explanation may be related to the time these lesions
require to develop and progress. In our series we were able to
study the evolution of the lesions in few patients who underwent a
second liver resection for metastasis recurrence. The sinusoidal
lesions persisted for several months after chemotherapy had been
discontinued. The histopathological findings suggest that fibrosis
persists, and, in the few cases we were able to follow for an
extended period (>49 months), may continue to progress and
reach considerable extension. The risk of evolution may be import-
ant, particularly for those patients who have to receive multiple
chemotherapy cycles to obtain better tumor responses. Finally, the
relationship between tumoral response and type of chemotherapy
received is under study. Preliminary results did not identify a
significant difference in the size, localization and number of
metastasis, evaluated by computed tomography scan prior to neo-
adjuvant therapy, between the control group and the group receiving
chemotherapy. No significant relationship has been observed
between these tumor characteristics and development of sinusoidal
lesion in the non-tumoral liver.
Our ability to evaluate the clinical relevance of our findings was
limited by the retrospective nature of this study. One would
suspect, however, that the constellation of the lesions described
here may result in an impairment of liver function in some
patients; it is also possible that the vascular lesions may limit the
regenerative ability of the liver after large hepatectomies.
In the light of these findings, we are currently carrying out a
prospective study to determine the laboratory and clinical effects
of oxaliplatin-induced liver toxicity during the course of and after
preoperative chemotherapy. We are also exploring ways to prevent
these toxic effects by using glutathione, a compound that has
recently been reported to be effective in the prevention of chemo-
therapy-associated neuropathy [27]. The use of glutathione in an
attempt to prevent liver injury has both biological plausibility and
experimental support: in a rat model, profound glutathione deple-
tion was found to play a role in the occurrence sinusoidal hepatic
toxicity [28–30]. Prevention of sinusoidal lesions was also
achieved experimentally in rats by maintaining the level of
hepatic nitric oxide (NO) through the administration of O(2)-vinyl
1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO), a
liver-selective NO-donating prodrug, metabolized by hepatic
enzymes to release NO within the liver [16, 31]. The use of such
drugs in humans has not yet been reported in veno-occlusive
disease, but it is conceivable that in the future they may acquire a
role in the prevention of vascular liver toxicity.
In conclusion, we have shown that half of the patients who
underwent neo-adjuvant chemotherapy, and at least three-quarters
of patients who received oxaliplatin, had specific liver lesions.
Sinusoidal injury complicated by fibrosis and veno-occlusive
lesions should be included in the list of the adverse side-effects of
systemic chemotherapy for colorectal tumors, particularly in
connection with the use of oxaliplatin. The clinical consequences
of these sinusoidal lesions and venular obstruction also need to be
evaluated with respect to the potential impairement of liver
regeneration after extended resection.
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